US Human Microbiome Market - Industry Trends and Forecast to 2029

U.S. human microbiome market is projected to register a substantial CAGR of 23.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
 

Market Segmentation
U.S. Human Microbiome Market, By Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs, Supplements, Fecal Microbiota Transplant, and Others), Application (Therapeutic and Diagnostic), Disease (Infectious Disease, Dermatological Disorders, Autoimmune Disorder, Metabolic Disorder, Gastrointestinal Disorders, Cancer, Mental Disorders, C. Difficile Infection, Primary Hyperoxyureasolution-Phase, and Others), Technology (Genomics, Proteomics, and Metabolomics), Type (Small Molecule and Biologic), End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Hypermarket/Supermarket, Clinics, and Others), Distributor (Direct Tender and Retail Sales), Country (U.S.) Industry Trends and Forecast to 2029.

One of the major factors contributing to the growth of U.S. human microbiome market is:

• Rising incidence and prevalence of lifestyle disorders and chronic diseases is expected to drive the growth of the market

Market Players

The key market players for U.S. human microbiome market are listed below:

• 4D pharma plc
• Evelo Biosciences, Inc.
• Viome Life Sciences, Inc.
• Finch Therapeutics Group, Inc.
• OptiBiotix HEALTH PLC
• BiomX
• Sun Genomics
• Metabiomics
• Osel Inc
• Ferring B.V.  
• Merck KGaA
• Assembly Biosciences, Inc.
• Synthetic Biologics, Inc.
• FlightPath Biosciences, Inc.
• Vedanta Biosciences, Inc.
• Second Genome